Physician profile
Joel Spitz
NPI 1699867408
$2,521.14
in general payments reported to CMS, 2019-2025
14 companies · $940 in 2025
The $940 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $215 · 2021: $71.75 · 2022: $210 · 2023: $276 · 2024: $667 · 2025: $940.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.50 |
| Education | $154.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $1,037.55 | 2022-2025 | Aklief |
| Janssen Biotech, INC. | $658.14 | 2019-2024 | Tremfya |
| Abbvie INC. | $226.09 | 2020-2025 | |
| Arcutis Biotherapeutics, INC. | $165.46 | 2024-2025 | Zoryve |
| Journey Medical Corporation | $89.74 | 2023 | |
| Leo Pharma INC. | $62.26 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $62.20 | 2022-2023 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $60.54 | 2022-2024 | Dupixent |
| Almirall LLC | $46.70 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $42.28 | 2020-2021 | |
| Cipher Pharmaceuticals US LLC | $24.99 | 2025 | Spinosad, Natroba |
| Incyte Corporation | $15.34 | 2022 | |
| Strata Skin Sciences, INC. | $15.20 | 2025 | Xtrac |
| Janssen Scientific Affairs, LLC | $14.65 | 2024 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Spitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.